The combination of mdpv and ethanol results in decreased cathinone and increased alcohol levels. Study of such pharmacological interaction.

Abstract

Methylenedioxypyrovalerone (MDPV) is a new cathinone psychostimulant acting as a selective dopamine transporter blocker. Due to the concomitant consumption of ethanol (EtOH) and new psychoactive substances it is of relevance to explore the pharmacological interaction between MDPV and EtOH. In locomotor activity assays, EtOH (1 g/kg i.p.) elicited a reduction in the stimulant effect induced by low doses of MDPV (0.1‐0.3 mg/kg, s.c) in rats, jointly with a decrease in blood and brain MDPV concentrations. Experiments in rat liver microsomes showed different effects depending on [MDPV]/[EtOH] relationship, evidencing, at certain concentrations, the enhancing effect of EtOH on MDPV metabolism. Therefore, it seems that EtOH interacts with MDPV at microsomal level, increasing its metabolic rate. The interaction between both substances was also supported by results on plasma EtOH concentration, which were significantly increased by MDPV, in such a manner that EtOH elimination rate was significantly reduced. The possible toxicological impact of this phenomenon deserves further investigation. In contrast, the rewarding properties of MDPV were unaltered by EtOH. Microdialysis experiments verified that in the NAcc, both substances could also act synergistically, in such a manner that extracellular dopamine concentrations are maintained. Finally, if the psychostimulant effect induced by MDPV decreases with EtOH, it could favor the boosting and re-dosing in search of the desired effects. However, as the rewarding effect of each dose of the substance would not decrease, the addictive liability could increase considerably. Moreover, we must warn about the increase in EtOH concentrations when consumed concomitantly with MDPV.

Document Type

Article


Accepted version

Language

English

Publisher

Elsevier B.V.

Related items

Versió postprint del document publicat a: https://doi.org/10.1016/j.pnpbp.2017.02.011

Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2017, vol. 76, p. 19-28

https://doi.org/10.1016/j.pnpbp.2017.02.011

Recommended citation

This citation was generated automatically.

Rights

cc-by-nc-nd (c) Elsevier B.V., 2017

http://creativecommons.org/licenses/by-nc-nd/3.0/es

This item appears in the following Collection(s)